<DOC>
	<DOC>NCT00189124</DOC>
	<brief_summary>The purpose of this study is to evaluate the effect of DHEA on endothelial dysfunction in patients with systemic lupus by measuring: 1. changes in brachial artery flow-mediated dilatation (FMD) and 2. changes in biomarkers of cardiovascular risk. Patients will be enrolled in a randomized, double-blinded crossover trial of DHEA or placebo for ten weeks, then crossed over to the alternate treatment arm after a six-week washout period. HYPOTHESIS: Dehydroepiandrosterone (DHEA) administration in premenopausal women with SLE modifies cardiovascular risk by improving vascular endothelial function and other biomarkers associated with cardiovascular heart disease.</brief_summary>
	<brief_title>Dehydroepiandrosterone (DHEA) in Systemic Lupus Erythematosus (SLE) for Coronary Artery Disease (CAD) Prevention</brief_title>
	<detailed_description />
	<mesh_term>Lupus Erythematosus, Systemic</mesh_term>
	<mesh_term>Dehydroepiandrosterone</mesh_term>
	<criteria>Female Member of the Michigan Lupus Cohort Meet the American College of Rheumatology (ACR) criteria for SLE Premenopausal Smoker Diabetic Prednisone dose &gt; 10 mg</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Systemic Lupus Erythematosus</keyword>
	<keyword>Dehydroepiandrosterone (DHEA)</keyword>
	<keyword>DHEA</keyword>
	<keyword>SLE</keyword>
	<keyword>Lupus</keyword>
</DOC>